| 15.77 0.22 (1.41%) | 05-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 23.67 | 1-year : | 27.69 |
| Resists | First : | 20.26 | Second : | 23.7 |
| Pivot price | 15.63 |
|||
| Supports | First : | 14.69 | Second : | 12.23 |
| MAs | MA(5) : | 15.69  |
MA(20) : | 16.19 |
| MA(100) : | 29.03 |
MA(250) : | 26.76 |
|
| MACD | MACD : | -2.5 |
Signal : | -3.2 |
| %K %D | K(14,3) : | 44.5 |
D(3) : | 33.2 |
| RSI | RSI(14): 31.1 |
|||
| 52-week | High : | 48.31 | Low : | 9.18 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TRML ] has closed below upper band by 35.4%. Bollinger Bands are 92.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 15.96 - 16.08 | 16.08 - 16.16 |
| Low: | 15.21 - 15.33 | 15.33 - 15.42 |
| Close: | 15.61 - 15.8 | 15.8 - 15.94 |
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.
Thu, 09 May 2024
Vivo Capital LLC Buys New Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - MarketBeat
Mon, 29 Apr 2024
Short Interest in Tourmaline Bio, Inc. (NASDAQ:TRML) Increases By 20.9% - MarketBeat
Sat, 13 Apr 2024
Tourmaline Bio (NASDAQ:TRML) Shares Gap Up to $19.91 - Defense World
Fri, 22 Mar 2024
Tourmaline Bio might see weakness today after Roche MG data, says Truist - TipRanks.com - TipRanks
Fri, 22 Mar 2024
Tourmaline Bio: Sinking On Rival's Stodgy Data - I'm Slightly Bearish (NASDAQ:TRML) - Seeking Alpha
Wed, 20 Mar 2024
institutional investors of Tourmaline Bio, Inc. (NASDAQ:TRML) must be disappointed after last week's 12% drop - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 26 (M) |
| Shares Float | 16 (M) |
| Held by Insiders | 22.6 (%) |
| Held by Institutions | 57.7 (%) |
| Shares Short | 1,790 (K) |
| Shares Short P.Month | 663 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -25.9 % |
| Return on Equity (ttm) | -39.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.77 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -28 (M) |
| Levered Free Cash Flow | -25 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -14.41 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|